Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 11/20 | 0.69 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606153 | 0.90 | CXCR2 (0.54) | CXCR2LMNAPKMTDP1L3MBTL1 | |
| SCHEMBL3610346 | 0.86 | CXCR2 (0.65) | CXCR2BRD4DCUN1D1 | |
| SCHEMBL3605175 | 0.85 | CXCR2 (0.65) | CXCR2DCUN1D1LMNAPKMTDP1 | |
| SCHEMBL13444973 | 0.85 | CXCR2 (0.63) | CXCR2DCUN1D1 | |
| SCHEMBL3611711 | 0.83 | CXCR2 (0.53) | CXCR2 | |
| SCHEMBL3594813 | 0.83 | CXCR2 (0.66) | CXCR2 | |
| SCHEMBL13444963 | 0.82 | CXCR2 (0.51) | CXCR2DCUN1D1 | |
| SCHEMBL3599639 | 0.82 | CXCR2 (0.61) | CXCR2 | |
| SCHEMBL13444972 | 0.81 | CXCR2 (0.63) | CXCR2 | |
| SCHEMBL3601099 | 0.81 | CXCR2 (0.53) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | claimed |
| EP-2086947-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| EP-2086947-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885BRD4 2479/4885DCUN1D1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.